European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

How do you manage post-thyroidectomy hypocalcaemia?
Physician and surgeon members of the the British Association of Endocrine and Thyroid Surgeons (BAETS) and/or the Society for Endocrinology (SfE) are encouraged to complete ashort survey on the management of post-thyroidectomy hypocalcaemia.Jeremy Turner (SfE) and Saba Balasubramanian (BAETS) aim to use your input to We are develop a protocol for managing hypocalcaemia/hypoparathyroidism after thyroid surgery that would be applicable across the UK.Your contributions would be much appreciated and the final protocol will be available to members of SfE and BAETS.Complete the survey now. (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 5, 2019 Category: Endocrinology Source Type: news

Hormonal injection approved for treatment of hypoparathyroidism
The FDA recently approved a parathyroid hormone product, Natpara (NPS Pharmaceuticals), to control hypocalcaemia in patients with hypoparathyroidism. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 28, 2015 Category: Endocrinology Source Type: news

Postoperative symptomatic hypocalcaemia linked to preoperative vitamin D deficiency in thyroid cancer patients
In a study presented at the American Thyroid Association Annual Meeting researchers from Yonsei University College of Medicine evaluated postoperative thyroid cancer patients to determine if preoperative Vitamin D deficiency is associated with postoperative symptomatic hypocalcaemia. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 4, 2014 Category: Endocrinology Source Type: news

Society for Endocrinology Emergency Endocrine Guidance
The Society for Endocrinology’s Clinical Committee has produced Emergency Endocrine Guidance for three potentially life-threatening conditions which would necessitate urgent treatment: Acute Hypercalcaemia, Acute Hypocalcaemia (in adults) and Pituitary Apoplexy. These documents are targeted at health professionals and the emergency services and aim to provide emergency guidance through the initial phase of assessment and management of the patient. These documents are available to download from the Society website and will be published for distribution in the near future. We...
Source: Society for Endocrinology - July 15, 2013 Category: Endocrinology Source Type: news

How is acute hyperphosphataemia treated in adults?
Source: Leeds Medicines Information Centre Area: Evidence > Medicines Q & A There are no national guidelines for the treatment of acute hyperphosphataemia, and practice varies widely between hospital Trusts. The guidance in this Medicines Q&A reflects practice at Leeds Teaching Hospitals NHS Trust. The cause of the hyperphosphataemia should be established and treated. Most patients with hyperphosphataemia are asymptomatic. If symptoms are present, they are usually reflective of underlying contributory pathologies. Acute severe hyperphosphataemia with symptomatic hypocalcaemia can be life-threatening and di...
Source: NeLM - Medicines Q and A - February 26, 2013 Category: Drugs & Pharmacology Source Type: news